Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

fresenius kabi ab - glucosa anhidra (eq. a 14,3 g de glucosa monohidratada); aminoven 10 % con electrolitos.; smoflipid 20 %. - emulsión para infusión iv - 13 g/100 ml

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

laboratorios fresenius kabi deutschland gmbh [de] germany - 7.50g + 8.00g + 13.0g + 12.0 g + 8.51g + 3.12g + 3.75g + 4.40g + 2.01g + 9.00g + 4.15g + 9.30g + 9.71g + 4.76g + 7.67g + 5.176g + 0.40g + 2.62g + 0.70g + 0.52g - soluciÓn para infusiÓn - l-arginina????????? ????? ?????7.50 g l-isoleucina 8.00 g l-leucina????????????? ??????. 13.0 g l-lisina monoacetato 12.0 g = l-lisina 8.51 g l-metionina 3.12 g l-fenilalanina 3.75 g l-treonina 4.40 g l- triptófano 2.01 g l-valina 9.00 g glicina 4.15 g l-alanina 9.30 g l-prolina 9.71 g l-histidina 4.76 g l-serina 7.67 g n-acetyl-l-tirosina 5.176 g l-taurina 0.40 g l-malic acid 2.62 g n-acetyl-l-cisteina 0.70 g

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

laboratorios fresenius kabi deutschland gmbh [de] germany - aceite de soya 60.0 mg trigliceridos de cadena media 60.0 mg aceite de oliva 50.0 mg aceite de pescado rico en omega 3 30.0 mg - emulsion - cada ml contiene: aceite de soya 60.0 mg trigliceridos de cadena media 60.0 mg aceite de oliva 50.0 mg aceite de pescado rico en omega 3 30.0 mg

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi deutschland gmbh [de] germany - poly(o-2-hidroxietil)almidon 60,00 g. - solucion inyectable para infusion - cada 1000 ml contiene poly(o-2-hidroxietil)almidon 60,00 g. sustitucion molar 0.38 - 0.45 peso molecular medio = 130,00 da cloruro de sodio 9,00 g. electrolitos: na+ 154 mmol/l cl- 154 mmol/l

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi deutschland gmbh alemania - linezolid 2 mg/ml - solucion para infusion - cada ml contiene: linezolid 2.00 mg

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

fresenius kabi austria gmbh. - l-alanina; l-arginina; glicina; l-histidina; l-isoleucina; l-leucina; l-acetato de lisina (eq. a 0,66 g de l-lisina); l-metionina; l-fenilalanina; l-prolina; l-serina; taurina; l-treonina; l-triptófano; l-tirosina; l-valina - solución para infusión iv - 1400 mg/100 ml; 1200 mg/100 ml; 1100 mg/100 ml; 300 mg/100 ml; 500 mg/100 ml; 740 mg/100 ml; 931 mg/100 ml; 430 mg/100 ml; 510 mg/100 ml; 1120 mg/100 ml; 650 mg/100 ml; 100 mg/100 ml; 440 mg/100 ml; 200 mg/100 ml; 40 mg/100 ml; 620 mg/100 ml

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

fresenius kabi austria gmbh. - n(2)-l-alanil-l-glutamina - solución concentrada para infusión iv - 200 mg/ml

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

fresenius kabi austria gmbh. - aceite de soja; triglicéridos de cadena media; aceite de oliva refinado; aceite de pescado refinado rico en ácidos omega-3 - emulsión para infusión iv - 6 g/100 ml; 6 g/100 ml; 5 g/100 ml; 3 g/100 ml

Unión Europea - español - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - pegfilgrastim - neutropenia - inmunoestimulantes, , factores estimulantes de colonias - reducción en la duración de la neutropenia y la incidencia de neutropenia febril en pacientes adultos tratados con quimioterapia citotóxica para la malignidad (con la excepción de crónica mieloide leucemia y mielodisplásicos síndromes).

Unión Europea - español - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - inmunosupresores - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.